Informações:
Falhas:
ID
34147
Descrição
A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01598285
Link
https://clinicaltrials.gov/show/NCT01598285
Palavras-chave
Versões (1)
- 14/01/2019 14/01/2019 -
Titular dos direitos
GSK group of companies
Transferido a
14 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Breast Cancer Invasive Nos NCT01598285
Eligibility Breast Cancer Invasive Nos NCT01598285
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer Invasive Nos NCT01598285
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
ID.1
Item
patients with breast cancer, at a disseminated stage
boolean
ID.2
Item
patients treated with bevacizumab in combination with weekly paclitaxel as first line chemotherapy and who have progressed
boolean
ID.3
Item
alive patients authorizing the extraction and analysis of their biological samples.
boolean
ID.4
Item
patients with a second neoplasia
boolean
ID.5
Item
deceased patients
boolean
ID.6
Item
patients who have not agreed to participate in the study
boolean
ID.7
Item
her2 positive patients
boolean
ID.8
Item
patients with cns metastases when first treated with bevacizumab in combination with paclitaxel
boolean
ID.9
Item
patients with local-regional recurrence only and
boolean
ID.10
Item
patients with status ned (resected metastases)
boolean